title: Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved.
abstract: BACKGROUND
  Pseudomyxoma peritonei is a diffuse peritoneal malignancy that generally originates form a perforated appendiceal tumor. Optimal treatment requires extensive surgical resection to achieve complete cytoreduction combined with hyperthermic intraperitoneal chemotherapy. In a proportion of patients this is impossible, in particular, owing to extensive irresectable small-bowel involvement. There is ongoing debate as to the role of maximal tumor debulking in such cases.
  
  
  OBJECTIVE
  : The aim of this study was to assess the outcomes of patients who underwent major tumor debulking for pseudomyxoma peritonei of appendiceal origin and to compare outcomes with patients who had complete cytoreduction during the same period.
  
  
  METHODS
  This is a retrospective study.
  
  
  METHODS
  This investigation was conducted at a tertiary referral center for peritoneal surface malignancy.
  
  
  METHODS
  A prospective database of 953 consecutive patients with peritoneal malignancy undergoing surgery at a UK national referral center between 1994 and 2012 was analyzed. Of these patients, 748 (78%) had surgery for pseudomyxoma peritonei of appendiceal origin.
  
  
  METHODS
  Survival, morbidity, and mortality in both groups were compared. Univariate and multivariate analyses were performed to identify negative prognostic factors in the group that underwent major tumor debulking.
  
  
  RESULTS
  Complete cytoreductive surgery was achieved in 543/748 (73%) patients, and 205 (27%) had maximal tumor debulking. Median age was 56 years (172 (31.7%) men) in the complete cytoreductive surgery group and 59 years (108 (52.7%) men) in the maximal tumor debulking group. Overall survival at 3, 5, and 10 years was 90%, 82%, and 64% in the complete cytoreductive group and 47%, 30%, and 22% in the maximal tumor debulking group. The median survival in the maximal tumor debulking group was 32.8 months (95% CI, 24.1-41.5).
  
  
  CONCLUSIONS
  The retrospective analysis of prospective data was a limitation of this study.
  
  
  CONCLUSIONS
  Maximal tumor debulking may help patients with pseudomyxoma peritonei in whom complete cytoreduction cannot be achieved with almost half alive at 3 years with long-term survival in some.
authors.affiliation: Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, United Kingdom.
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Dayal
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Taflampas
authors.forename: Stefan
authors.initials: S
authors.lastname: Riss
authors.forename: Kandiah
authors.initials: K
authors.lastname: Chandrakumaran
authors.forename: Thomas D
authors.initials: TD
authors.lastname: Cecil
authors.forename: Faheez
authors.initials: F
authors.lastname: Mohamed
authors.forename: Brendan J
authors.initials: BJ
authors.lastname: Moran
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use; D015999:Multivariate Analysis; D018365:Neoplasm, Residual; D010534:Peritoneal Neoplasms / Q000601:surgery* / Q000628:therapy; D011553:Pseudomyxoma Peritonei / Q000601:surgery* / Q000628:therapy; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D016685:Mitomycin